Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported a strong financial performance for Q3 2021, with net revenues reaching $112.2 million, up 34% from $83.4 million in Q3 2020. The GAAP net income was $29.5 million, or $0.59 per share. Key product drivers included Primatene Mist, epinephrine, and glucagon, showing substantial sales increases. The company also highlighted a robust pipeline with several products aimed at a combined market size exceeding $27 billion. The significant gain from the restructuring of its Chinese subsidiary contributed to non-operating income growth.

Positive

• Net revenues increased by 34% year-over-year to $112.2 million.
• GAAP net income rose to $29.5 million, or $0.59 per share, compared to $3.9 million the previous year.
• Significant sales growth in key products: Primatene Mist (28%), epinephrine (159%), and glucagon (new product launch).
• Improved gross profit margin of 46%, up from 44% in the previous year.
• Strong development pipeline with 5 ANDAs and 3 biosimilars targeting a combined market size of approximately $15.5 billion.

Negative

• Cost of revenues increased by 30%, leading to higher operating expenses.
• Decline in enoxaparin sales by 31%, indicating potential competitive risks.
• Research and development expenses decreased by 39%, which may affect long-term growth if not addressed.

Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2021.

Third Quarter Highlights

• Net revenues of $112.2 million for the third quarter
• GAAP net income of $29.5 million, or $0.59 per share, for the third quarter
• Adjusted non-GAAP net income of $23.0 million, or $0.46 per share, for the third quarter

Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We delivered record sales due to the continued momentum driven by the strength of our glucagon, Primatene Mist ^® and our epinephrine products. These products should continue to be the primary drivers of growth until we receive further approvals for products in our pipeline, which we project will happen in 2022."

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2021				2020				2021				2020
		(in thousands, except per share data)
Net revenues		$	112,198			$	83,431			$	316,881			$	253,925
GAAP net income attributable to Amphastar		$	29,548			$	3,919			$	42,356			$	7,676
Adjusted non-GAAP net income attributable to Amphastar*		$	22,998			$	7,629			$	47,166			$	23,622
GAAP diluted EPS attributable to Amphastar stockholders		$	0.59			$	0.08			$	0.85			$	0.16
Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders*		$	0.46			$	0.15			$	0.95			$	0.48

---

* Adjusted non-GAAP net income attributable to Amphastar and Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

Third Quarter Results

		Three Months Ended
		September 30,								Change
		2021				2020				Dollars				%
		(in thousands)
Net revenues:
Primatene Mist ®		$	16,561			$	12,988			$	3,573				28	%
Epinephrine			13,892				5,370				8,522				159	%
Glucagon			12,189				-				12,189				N/A
Lidocaine			11,649				10,657				992				9	%
Phytonadione			11,591				10,470				1,121				11	%
Enoxaparin			8,034				11,647				(3,613	)			(31	)%
Naloxone			8,028				8,739				(711	)			(8	)%
Other finished pharmaceutical products			27,046				21,464				5,582				26	%
Total finished pharmaceutical products net revenues		$	108,990			$	81,335			$	27,655				34	%
API			3,208				2,096				1,112				53	%
Total net revenues		$	112,198			$	83,431			$	28,767				34	%

Changes in net revenues were primarily driven by:

• Primatene Mist ^® increased volumes resulting from the continued success of our advertising campaign
• Glucagon for injection emergency kit, which was launched in the first quarter of 2021
• Epinephrine sales increased due to higher demand as a result of competitor shortages
• Other finished pharmaceutical product sales increased due to higher demand, largely due to competitors shortages

		Three Months Ended
		September 30,								Change
		2021				2020				Dollars				%
		(in thousands)
Net revenues		$	112,198			$	83,431			$	28,767				34	%
Cost of revenues			61,015				46,923				14,092				30	%
Gross profit		$	51,183			$	36,508			$	14,675				40	%
as % of net revenues			46	%			44	%

Changes in the cost of revenues and the resulting increase in gross margin were primarily driven by:

• Increased sales of higher-margin products such as Primatene Mist ^® , epinephrine injection multi-dose vials, and glucagon
• Partially offset by increased cost for heparin, the starting material for enoxaparin, and lower pricing for enoxaparin

		Three Months Ended
		September 30,								Change
		2021				2020				Dollars				%
		(in thousands)
Selling, distribution, and marketing		$	4,745			$	3,673			$	1,072				29	%
General and administrative			10,910				11,674				(764	)			(7	)%
Research and development			10,759				17,644				(6,885	)			(39	)%
Non-operating income, net			12,877				3,561				9,316				262	%

• Selling, distribution, and marketing expenses increased primarily due to the marketing and distribution expenses for Primatene Mist ^®
• General and administrative expenses decreased primarily due to a decrease in legal expenses
• Research and development expenses decreased due to:
  • A decrease in clinical trial expense as a result of the completion of one of our clinical trial studies at the end of 2020
  • A decrease in expenses in China due to the restructuring of ANP and the deconsolidation of Hanxin and its subsidiaries
• Non-operating income, net, increased as a result of the $13.6 million gain on the deconsolidation of Hanxin relating to the ANP restructuring

Cash flow provided by operating activities for the nine months ended September 30, 2021, was $57.6 million.

Pipeline Information

The Company currently has five ANDAs on file with the FDA targeting products with a market size of approximately $2.5 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and eight generic products in development targeting products with a market size of approximately $12 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2021. The Company is currently developing multiple proprietary products with injectable and intranasal dosage forms.

Amphastar's Chinese subsidiary, ANP, currently has 17 Drug Master Files, or DMFs, on file with the FDA and is developing several additional DMFs.

Company Information

Amphastar is a bio pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com .

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ^® , Primatene Mist ^® , Amphadase ^® , and Cortrosyn ^® , are the property of Amphastar.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) attributed to Amphastar and (ii) Adjusted non-GAAP diluted EPS attributed to Amphastar's stockholders, which exclude amortization expense, share-based compensation, impairment charges, executive severance expense, and legal settlements, in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Conference Call Information

The Company will hold a conference call to discuss its financial results today, November 8, 2021, at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, five minutes before the conference.

The call can also be accessed on the Investors page on the Company's website at www.amphastar.com .

Forward-Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance, backlog, sales and marketing of our products, market size and growth, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, our share buyback program, the impact of the restructuring of ANP, and other future events, such as the impact of the COVID-19 pandemic including its variants and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 9, 2021. In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic including its variants, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact Information:

Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 980-9484

Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2021				2020				2021				2020
Net revenues		$	112,198			$	83,431			$	316,881			$	253,925
Cost of revenues			61,015				46,923				173,376				147,417
Gross profit			51,183				36,508				143,505				106,508
Operating expenses:
Selling, distribution, and marketing			4,745				3,673				13,411				10,993
General and administrative			10,910				11,674				40,813				38,344
Research and development			10,759				17,644				43,646				49,096
Total operating expenses			26,414				32,991				97,870				98,433
Income from operations			24,769				3,517				45,635				8,075
Non-operating income, net			12,877				3,561				11,342				3,304
Income before income taxes			37,646				7,078				56,977				11,379
Income tax provision			6,686				2,285				13,436				4,490
Net income		$	30,960			$	4,793			$	43,541			$	6,889
Net income (loss) attributable to non-controlling interests		$	1,412			$	874			$	1,185			$	(787	)
Net income attributable to Amphastar		$	29,548			$	3,919			$	42,356			$	7,676
Net income per share attributable to Amphastar stockholders:
Basic		$	0.62			$	0.08			$	0.89			$	0.16
Diluted		$	0.59			$	0.08			$	0.85			$	0.16
Weighted-average shares used to compute net income per share attributable to Amphastar stockholders:
Basic			48,022				47,496				47,758				46,886
Diluted			50,009				49,848				49,693				48,922

Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands, except share data)

		September 30,				December 31,
		2021				2020
ASSETS
Current assets:
Cash and cash equivalents		$	106,610			$	92,642
Restricted cash			235				1,865
Short-term investments			8,021				12,977
Restricted short-term investments			2,200				2,200
Accounts receivable, net			78,090				66,005
Inventories			100,240				96,831
Income tax refunds and deposits			520				385
Prepaid expenses and other assets			7,755				6,777
Total current assets			303,671				279,682
Property, plant, and equipment, net			242,924				260,055
Finance lease right-of-use assets			428				612
Operating lease right-of-use assets			27,663				20,042
Equity method investment			4,193				-
Goodwill and intangible assets, net			39,192				40,615
Other assets			11,610				5,250
Deferred tax assets			21,996				24,980
Total assets		$	651,677			$	631,236
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	88,911			$	95,504
Income taxes payable			3,960				1,077
Current portion of long-term debt			2,256				12,263
Current portion of operating lease liabilities			2,862				3,357
Total current liabilities			97,989				112,201
Long-term reserve for income tax liabilities			4,709				4,709
Long-term debt, net of current portion and unamortized debt issuance costs			75,552				34,186
Long-term operating lease liabilities, net of current portion			25,466				17,464
Deferred tax liabilities			2,901				741
Other long-term liabilities			14,884				13,212
Total liabilities			221,501				182,513
Commitments and contingencies
Stockholders' equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock: par value $0.0001; 300,000,000 shares authorized; 56,051,662 and 47,982,690 shares issued and outstanding as of September 30, 2021 and 54,760,922 and 47,495,439 shares issued and outstanding as of December 31, 2020, respectively			6				5
Additional paid-in capital			412,917				410,061
Retained earnings			160,577				117,773
Accumulated other comprehensive loss			(6,277	)			(3,721	)
Treasury stock			(137,047	)			(121,812	)
Total Amphastar Pharmaceuticals, Inc. stockholders' equity			430,176				402,306
Non-controlling interests			-				46,417
Total equity			430,176				448,723
Total liabilities and stockholders' equity		$	651,677			$	631,236

Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2021				2020				2021				2020
GAAP net income		$	30,960			$	4,793			$	43,541			$	6,889
Adjusted for:
Intangible amortization			377				262				930				771
Share-based compensation			3,919				4,370				14,837				13,846
Impairment of long-lived assets			25				130				339				160
Gain on ANP Restructuring			(13,587	)			-				(13,587	)			-
Expense related to executive separation agreement			-				-				-				4,869
Reserves for litigation and settlements			-				-				2,991				-
Income tax (benefit) provision on pre-tax adjustments			921				(943	)			(1,614	)			(3,392	)
Non-GAAP net income		$	22,615			$	8,612			$	47,437			$	23,143
Non-GAAP net income (loss) attributable to non-controlling interests		$	(383	)		$	983			$	271			$	(479	)
Non-GAAP net income attributable to Amphastar		$	22,998			$	7,629			$	47,166			$	23,622
Non-GAAP net income per share attributable to Amphastar stockholders:
Basic		$	0.48			$	0.16			$	0.99			$	0.50
Diluted		$	0.46			$	0.15			$	0.95			$	0.48
Weighted-average shares used to compute non-GAAP net income per share attributable to Amphastar stockholders:
Basic			48,022				47,496				47,758				46,886
Diluted			50,009				49,848				49,693				48,922

		Three Months Ended September 30, 2021
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating income (expense), net				Income tax provision (benefit)				Non-controlling interest adjustment
GAAP		$	61,015			$	4,745			$	10,910			$	10,759			$	12,877			$	6,686			$	1,412
Intangible amortization			(242	)			-				(135	)			-				-				-				4
Share-based compensation			(889	)			(164	)			(2,533	)			(333	)			-				-				8
Impairment of long-lived assets			-				-				(25	)			-				-				-				4
Gain on ANP Restructuring			-				-				-				-				(13,587	)			-				(2,062	)
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				(921	)			251
Non-GAAP		$	59,884			$	4,581			$	8,217			$	10,426			$	(710	)		$	5,765			$	(383	)

		Three Months Ended September 30, 2020
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating income (expense), net				Income tax provision (benefit)				Non-controlling interest adjustment
GAAP		$	46,923			$	3,673			$	11,674			$	17,644			$	3,561			$	2,285			$	874
Intangible amortization			(229	)			-				(33	)			-				-				-				12
Share-based compensation			(947	)			(120	)			(2,899	)			(404	)			-				-				117
Impairment of long-lived assets			(19	)			-				(111	)			-				-				-				8
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				943				(28	)
Non-GAAP		$	45,728			$	3,553			$	8,631			$	17,240			$	3,561			$	3,228			$	983

		Nine Months Ended September 30, 2021
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating income (expense), net				Income tax provision (benefit)				Non-controlling interest adjustment
GAAP		$	173,376			$	13,411			$	40,813			$	43,646			$	11,342			$	13,436			$	1,185
Intangible amortization			(728	)			-				(202	)			-				-				-				26
Share-based compensation			(2,967	)			(438	)			(10,069	)			(1,363	)			-				-				870
Impairment of long-lived assets			(84	)			-				(33	)			(222	)			-				-				7
Gain on ANP Restructuring			-				-				-				-				(13,587	)			-				(2,062	)
Reserves for litigation and settlements			-				-				(1,295	)			-				1,696				-				-
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				1,614				245
Non-GAAP		$	169,597			$	12,973			$	29,214			$	42,061			$	(549	)		$	15,050			$	271

		Nine Months Ended September 30, 2020
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating income (expense), net				Income tax provision (benefit)				Non-controlling interest adjustment
GAAP		$	147,417			$	10,993			$	38,344			$	49,096			$	3,304			$	4,490			$	(787	)
Intangible amortization			(670	)			-				(101	)			-				-				-				34
Share-based compensation			(3,276	)			(350	)			(8,851	)			(1,369	)			-				-				330
Impairment of long-lived assets			(32	)			-				(128	)			-				-				-				15
Expense related to executive separation agreement			-				-				(4,869	)			-				-				-				-
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				3,392				(71	)
Non-GAAP		$	143,439			$	10,643			$	24,395			$	47,727			$	3,304			$	7,882			$	(479	)

SOURCE: Amphastar Pharmaceuticals, Inc.

View source version on accesswire.com:
https://www.accesswire.com/671534/Amphastar-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-September-30-2021

FAQ

What were Amphastar Pharmaceuticals' Q3 2021 earnings?

Amphastar Pharmaceuticals reported Q3 2021 net revenues of $112.2 million and a GAAP net income of $29.5 million, or $0.59 per share.

How did key products perform for Amphastar in Q3 2021?

In Q3 2021, Primatene Mist sales increased by 28%, epinephrine sales surged by 159%, and glucagon was newly launched, contributing to revenue growth.

What is the market potential of Amphastar's product pipeline?

Amphastar has 5 ANDAs and 3 biosimilar products in development targeting a combined market size of over $15.5 billion.

What impact did the restructuring of Amphastar's Chinese subsidiary have?

The restructuring of Amphastar's Chinese subsidiary contributed to a significant increase in non-operating income, reporting a $13.6 million gain.

What are the challenges Amphastar faced in Q3 2021?

Challenges included a 31% decline in enoxaparin sales and a 39% decrease in research and development expenses.